RE:RE:RE:RE:RE:RE:RE:RE:RE:JPM
I believe I am very pragmatic about the products that Thera as in its hands.
On the other hand, you have been very positive about Thera over the last 2 years in expectation of the fantastic opportunity provided by Trorgazo. You might say you are right about this, but, on the other hand, results were clearly much lower than those anticipated 18 months ago. From quarter to quarter since that time you provided guidance that lowered these expectations and tried to justify them. It may be true that sales are turning for Trogarzo and that a significant increase might be on the horizon but this as not been confirmed by Thera’s management and no clear short term projection was provided by them.
NASH, on the other hand, was not even on the radar until recently and represents a new opportunity which was not even pursued or conducted by Thera. Although Thera jumped on the bandwagon and made it part of their mission, there is no clear path where they are going with this. To me that means they were surprised by the study and that did not have time to prepare a full strategy in regards to it.
The NASH opportunity should not be a mask or distraction to the current Trogarzo challenges that have to be addressed and resolved.
Vision, purposeful and well-planned objectives and directions are the stuff that makes great companies and results are the gauges by which they are measured. As it stands right now, we don’t have results we only have sales.
So here I am with about 100K of shares of this stuff and no clear view of how this company will maintain or bring significant value to their shareholders. Can’t even sell part of my stock because there is insufficient liquidity to do this without bringing this stock to its knee.
I am stuck to wait it out and I have even taken out my shares from my margin account and moved them in a cash account so they cannot be used for shorting purposes. I do hope some of you reading this post will do the same.
I will continue to criticize this company until they do the job like any other good company, which is to at least meet market expectations and provide all appropriate guidances on which they can be measured.